Rep. Thomas H. Kean, Jr. Sells Off Becton, Dickinson and Company (NYSE:BDX) Shares

Representative Thomas H. Kean, Jr. (Republican-New Jersey) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on June 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Becton, Dickinson and Company stock on May 21st. The trade occurred in the Representative’s “KEAN FAMILY PARTNERSHIP” account.

Representative Thomas H. Kean, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Check Point Software Technologies (NASDAQ:CHKP) on 6/1/2026.
• Purchased $1,001 – $15,000 in shares of EQT (NYSE:EQT) on 6/1/2026.
• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 5/14/2026.
• Sold $1,001 – $15,000 in shares of Analog Devices (NASDAQ:ADI) on 4/29/2026.
• Sold $1,001 – $15,000 in shares of Take-Two Interactive Software (NASDAQ:TTWO) on 4/21/2026.
• Sold $1,001 – $15,000 in shares of nVent Electric (NYSE:NVT) on 4/15/2026.
• Purchased $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 4/14/2026.
• Sold $1,001 – $15,000 in shares of First Citizens BancShares (NASDAQ:FCNCA) on 4/14/2026.
• Purchased $1,001 – $15,000 in shares of Amcor (NYSE:AMCR) on 3/31/2026.
• Sold $15,001 – $50,000 in shares of S&P Global (NYSE:SPGI) on 3/26/2026.

Becton, Dickinson and Company Trading Up 0.0%

Shares of NYSE:BDX traded up $0.02 during mid-day trading on Friday, reaching $158.10. 2,036,087 shares of the company were exchanged, compared to its average volume of 2,812,766. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.94 and a quick ratio of 0.55. The firm has a market cap of $43.56 billion, a price-to-earnings ratio of 40.02, a P/E/G ratio of 11.19 and a beta of 0.21. The firm’s 50-day simple moving average is $147.98 and its 200 day simple moving average is $169.33. Becton, Dickinson and Company has a 1 year low of $127.59 and a 1 year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the company earned $3.35 earnings per share. The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts forecast that Becton, Dickinson and Company will post 12.62 EPS for the current year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th were issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio is currently 106.33%.

Analyst Ratings Changes

A number of brokerages recently commented on BDX. Bank of America lowered their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a report on Friday, June 12th. Evercore increased their price target on shares of Becton, Dickinson and Company from $180.00 to $190.00 in a research report on Thursday, May 7th. Royal Bank Of Canada set a $175.00 price objective on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. TD Cowen reduced their target price on shares of Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating on the stock in a report on Monday, May 4th. Finally, Zacks Research upgraded shares of Becton, Dickinson and Company from a “strong sell” rating to a “hold” rating in a research note on Friday, April 10th. Seven research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $181.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Imprint Wealth LLC acquired a new stake in shares of Becton, Dickinson and Company in the third quarter valued at approximately $25,000. Steph & Co. raised its holdings in shares of Becton, Dickinson and Company by 95.6% in the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock worth $26,000 after acquiring an additional 65 shares during the last quarter. SHP Wealth Management purchased a new stake in shares of Becton, Dickinson and Company in the fourth quarter valued at $26,000. Prosperity Bancshares Inc purchased a new stake in Becton, Dickinson and Company during the 4th quarter worth about $29,000. Finally, WPG Advisers LLC raised its stake in Becton, Dickinson and Company by 64.2% in the 4th quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity

In related news, EVP Michael David Garrison sold 1,100 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total transaction of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The shares were sold at an average price of $146.35, for a total value of $404,511.40. Following the completion of the transaction, the chief executive officer owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 5,188 shares of company stock worth $765,120 over the last ninety days. 0.40% of the stock is owned by corporate insiders.

About Representative Kean

Thomas Kean Jr. (Republican Party) is a member of the U.S. House, representing New Jersey’s 7th Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027.

Kean (Republican Party) is running for re-election to the U.S. House to represent New Jersey’s 7th Congressional District. He declared candidacy for the 2026 election.

Thomas Kean Jr. lives in Westfield, New Jersey. Kean earned a master’s degree from the Tufts University Fletcher School of Law and Diplomacy. His career experience includes working with the Environmental Protection Agency during the George H.W. Bush administration and as an advisor to former U.S. Representative Bob Franks, a firefighter, and an emergency medical technician. Kean has served as the vice president of a fire department.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.